nach oben

Erschienen in:

01.05.2012 | Schwerpunkt

Kardiovaskuläre Effekte inkretinbasierter Therapien

verfasst von: Dr. M. Lehrke, N. Marx

Erschienen in: Herz | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Zusammenfassung

Eine pharmakologische Aktivierung des GLP-1-Systems hat sich als ein neuer Ansatz in der Therapie des Diabetes mellitus etabliert. Neben einer glukosesenkenden Wirkung werden GLP-1 vielfältige kardioprotektive Eigenschaften zugesprochen. So reduziert GLP-1 die Infarktgröße im Rahmen eines akuten Myokardinfarkts, was über eine Aktivierung antiapoptotischer Signalwege wie PI3-Kinase, Akt, und ERK1/2 vermittelt wird. Experimentelle und frühe klinische Daten postulieren zudem, dass GLP-1 über eine verbesserte Endothelfunktion und antiinflammatorische Eigenschaften atheroprotektiv wirkt und die linksventrikulären Pumpfunktion bei chronischer Herzinsuffizienz über eine insulinunabhängige zelluläre Glukoseaufnahme verbessert. Entsprechend ist auf eine Reduktion kardiovaskulärer Ereignisse unter GLP-1-basierender Therapie zu hoffen, was derzeit in Endpunktstudien untersucht wird.

UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352(9131):837–853CrossRef

Gerstein HC, Miller ME, Byington RP et al (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358(24):2545–2559PubMedCrossRef

Patel A, MacMahon S, Chalmers J et al (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358(24):2560–2572PubMedCrossRef

Duckworth W, Abraira C, Moritz T et al (2009) Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360(2):129–139PubMedCrossRef

Turnbull FM, Abraira C, Anderson RJ et al (2009) Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 52(11):2288–2298PubMedCrossRef

UK Prospective Diabetes Study (UKPDS) Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352(9131):854–865CrossRef

Schramm TK, Gislason GH, Vaag A et al (2011) Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J 32(15):1900–1908PubMedCrossRef

Simpson SH, Majumdar SR, Tsuyuki RT et al (2006) Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study. CMAJ 174(2):169–174PubMedCrossRef

Tzoulaki I, Molokhia M, Curcin V et al (2009) Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ 339:b4731PubMedCrossRef

10.

Ginsberg H, Plutzky J, Sobel BE (1999) A review of metabolic and cardiovascular effects of oral antidiabetic agents: beyond glucose-level lowering. J Cardiovasc Risk 6(5):337–346PubMed

11.

Baggio LL, Drucker DJ (2007) Biology of incretins: GLP-1 and GIP. Gastroenterology 132(6):2131–2157PubMedCrossRef

12.

Meier JJ, Nauck MA (2005) Glucagon-like peptide 1 (GLP-1) in biology and pathology. Diabetes Metab Res Rev 21(2):91–117PubMedCrossRef

13.

Mojsov S, Heinrich G, Wilson IB et al (1986) Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing. J Biol Chem 261(25):11880–11889PubMed

14.

Orskov C, Wettergren A, Holst JJ (1993) Biological effects and metabolic rates of glucagonlike peptide-1 7–36 amide and glucagonlike peptide-1 7–37 in healthy subjects are indistinguishable. Diabetes 42(5):658–661PubMedCrossRef

15.

Nikolaidis LA, Elahi D, Shen YT, Shannon RP (2005) Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 289(6):H2401–2408PubMedCrossRef

16.

Deacon CF, Johnsen AH, Holst JJ (1995) Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 80(3):952–957PubMedCrossRef

17.

Knudsen LB, Pridal L (1996) Glucagon-like peptide-1-(9–36) amide is a major metabolite of glucagon-like peptide-1-(7–36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. Eur J Pharmacol 318(2–3):429–435

18.

Vahl TP, Paty BW, Fuller BD et al (2003) Effects of GLP-1-(7–36)NH2, GLP-1-(7–37), and GLP-1-(9–36)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans. J Clin Endocrinol Metab 88(4):1772–1779PubMedCrossRef

19.

Deacon CF, Plamboeck A, Moller S, Holst JJ (2002) GLP-1-(9–36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion. Am J Physiol Endocrinol Metab 282(4):E873–E879PubMed

20.

Abu-Hamdah R, Rabiee A, Meneilly GS et al (2009) Clinical review: The extrapancreatic effects of glucagon-like peptide-1 and related peptides. J Clin Endocrinol Metab 94(6):1843–1852PubMedCrossRef

21.

Nauck MA (2011) Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. Am J Med 124(Suppl 1):3–18CrossRef

22.

Deacon CF, Carr RD, Holst JJ (2008) DPP-4 inhibitor therapy: new directions in the treatment of type 2 diabetes. Front Biosci 13:1780–1794PubMedCrossRef

23.

Ahren B (2009) Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin – diabetes control and potential adverse events. Best Pract Res Clin Endocrinol Metab 23(4):487–498PubMedCrossRef

24.

Hausenloy DJ, Yellon DM (2009) Preconditioning and postconditioning: underlying mechanisms and clinical application. Atherosclerosis 204(2):334–341PubMedCrossRef

25.

Hausenloy DJ, Yellon DM (2004) New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovasc Res 61(3):448–460PubMedCrossRef

26.

Bose AK, Mocanu MM, Carr RD et al (2005) Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 54(1):146–151PubMedCrossRef

27.

Matsubara M, Kanemoto S, Leshnower BG et al (2011) Single dose GLP-1-Tf ameliorates myocardial ischemia/reperfusion injury. J Surg Res 165(1):38–45PubMedCrossRef

28.

Nikolaidis LA, Doverspike A, Hentosz T et al (2005) Glucagon-like peptide-1 limits myocardial stunning following brief coronary occlusion and reperfusion in conscious canines. J Pharmacol Exp Ther 312(1):303–308PubMedCrossRef

29.

Noyan-Ashraf MH, Momen MA, Ban K et al (2009) GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 58(4):975–983PubMedCrossRef

30.

Ossum A, Deurs U van, Engstrom T et al (2009) The cardioprotective and inotropic components of the postconditioning effects of GLP-1 and GLP-1(9–36)a in an isolated rat heart. Pharmacol Res 60(5):411–417PubMedCrossRef

31.

Read PA, Khan FZ, Heck PM et al (2010) DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease. Circ Cardiovasc Imaging 3(2):195–201PubMedCrossRef

32.

Sokos GG, Bolukoglu H, German J et al (2007) Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting. Am J Cardiol 100(5):824–829PubMedCrossRef

33.

Sonne DP, Engstrom T, Treiman M (2008) Protective effects of GLP-1 analogues exendin-4 and GLP-1(9–36) amide against ischemia-reperfusion injury in rat heart. Regul Pept 146(1–3):243–249

34.

Timmers L, Henriques JP, Kleijn DP de et al (2009) Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol 53(6):501–510PubMedCrossRef

35.

Ban K, Noyan-Ashraf MH, Hoefer J et al (2008) Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 117(18):2340–2350PubMedCrossRef

36.

Bose AK, Mocanu MM, Carr RD, Yellon DM (2007) Myocardial ischaemia-reperfusion injury is attenuated by intact glucagon like peptide-1 (GLP-1) in the in vitro rat heart and may involve the p70s6 K pathway. Cardiovasc Drugs Ther 21(4):253–256PubMedCrossRef

37.

Ban K, Kim KH, Cho CK et al (2010) Glucagon-like peptide (GLP)-1(9–36)amide-mediated cytoprotection is blocked by exendin(9–39) yet does not require the known GLP-1 receptor. Endocrinology 151(4):1520–1531PubMedCrossRef

38.

Read PA, Khan FZ, Dutka DP (2012) Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease. Heart 98(5):408–413PubMedCrossRef

39.

Nikolaidis LA, Mankad S, Sokos GG et al (2004) Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 109(8):962–965PubMedCrossRef

40.

Kavianipour M, Ehlers MR, Malmberg K et al (2003) Glucagon-like peptide-1 (7–36) amide prevents the accumulation of pyruvate and lactate in the ischemic and non-ischemic porcine myocardium. Peptides 24(4):569–578PubMedCrossRef

41.

Kristensen J, Mortensen UM, Schmidt M et al (2009) Lack of cardioprotection from subcutaneously and preischemic administered liraglutide in a closed chest porcine ischemia reperfusion model. BMC Cardiovasc Disord 9:31PubMedCrossRef

42.

Sauve M, Ban K, Momen MA et al (2010) Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice. Diabetes 59(4):1063–1073PubMedCrossRef

43.

Huisamen B, Genis A, Marais E, Lochner A (2011) Pre-treatment with a DPP-4 inhibitor is infarct sparing in hearts from obese, pre-diabetic rats. Cardiovasc Drugs Ther 25(1):13–20PubMedCrossRef

44.

Ye Y, Keyes KT, Zhang C et al (2010) The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA. Am J Physiol Heart Circ Physiol 298(5):H1454–H1465PubMedCrossRef

45.

Lønborg J, Vejlstrup N, Kelbaek H et al (2011) Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J [Epub ahead of print]

46.

Mussig K, Oncu A, Lindauer P et al (2008) Effects of intravenous glucagon-like peptide-1 on glucose control and hemodynamics after coronary artery bypass surgery in patients with type 2 diabetes. Am J Cardiol 102(5):646–647PubMedCrossRef

47.

Ravassa S, Zudaire A, Carr RD, Diez J (2011) Antiapoptotic effects of GLP-1 in murine HL-1 cardiomyocytes. Am J Physiol Heart Circ Physiol 300(4):H1361–H1372PubMedCrossRef

48.

Quoyer J, Longuet C, Broca C et al (2010) GLP-1 mediates antiapoptotic effect by phosphorylating Bad through a beta-arrestin 1-mediated ERK1/2 activation in pancreatic beta-cells. J Biol Chem 285(3):1989–2002PubMedCrossRef

49.

Gros R, You X, Baggio LL et al (2003) Cardiac function in mice lacking the glucagon-like peptide-1 receptor. Endocrinology 144(6):2242–2252PubMedCrossRef

50.

Nikolaidis LA, Elahi D, Hentosz T et al (2004) Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 110(8):955–961PubMedCrossRef

51.

Vyas AK, Yang KC, Woo D et al (2011) Exenatide improves glucose homeostasis and prolongs survival in a murine model of dilated cardiomyopathy. PLoS One 6(2):e17178PubMedCrossRef

52.

Liu Q, Anderson C, Broyde A et al (2010) Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure. Cardiovasc Diabetol 9:76PubMedCrossRef

53.

Poornima I, Brown SB, Bhashyam S et al (2008) Chronic glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure-prone rat. Circ Heart Fail 1(3):153–160PubMedCrossRef

54.

Sokos GG, Nikolaidis LA, Mankad S et al (2006) Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 12(9):694–699PubMedCrossRef

55.

Halbirk M, Nørrelund H, Møller N et al (2010) Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure. Am J Physiol Heart Circ Physiol 298(3):H1096–H1102PubMedCrossRef

56.

Lopaschuk GD, Ussher JR, Folmes CD et al (2010) Myocardial fatty acid metabolism in health and disease. Physiol Rev 90(1):207–258PubMedCrossRef

57.

Lee L, Horowitz J, Frenneaux M (2004) Metabolic manipulation in ischaemic heart disease, a novel approach to treatment. Eur Heart J 25(8):634–641PubMedCrossRef

58.

Nikolaidis LA, Sturzu A, Stolarski C et al (2004) The development of myocardial insulin resistance in conscious dogs with advanced dilated cardiomyopathy. Cardiovasc Res 61(2):297–306PubMedCrossRef

59.

Bhashyam S, Fields AV, Patterson B et al (2010) Glucagon-like peptide-1 increases myocardial glucose uptake via p38alpha MAP kinase-mediated, nitric oxide-dependent mechanisms in conscious dogs with dilated cardiomyopathy. Circ Heart Fail 3(4):512–521PubMedCrossRef

60.

Nyström T, Gutniak MK, Zhang Q et al (2004) Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 287(6):E1209–E1215PubMedCrossRef

61.

Basu A, Charkoudian N, Schrage W et al (2007) Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride. Am J Physiol Endocrinol Metab 293(5):E1289–E1295PubMedCrossRef

62.

Richter G, Feddersen O, Wagner U et al (1993) GLP-1 stimulates secretion of macromolecules from airways and relaxes pulmonary artery. Am J Physiol 265(4 Pt 1):L374–L381PubMed

63.

Nyström T, Gonon AT, Sjöholm A, Pernow J (2005) Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism. Regul Pept 125(1–3):173–177

64.

Green BD, Hand KV, Dougan JE et al (2008) GLP-1 and related peptides cause concentration-dependent relaxation of rat aorta through a pathway involving KATP and cAMP. Arch Biochem Biophys 478(2):136–142PubMedCrossRef

65.

Garber A, Henry R, Ratner R et al (2009) Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 373(9662):473–481PubMedCrossRef

66.

Moretto TJ, Milton DR, Ridge TD et al (2008) Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 30(8):1448–1460PubMedCrossRef

67.

Ogawa S, Ishiki M, Nako K et al (2011) Sitagliptin, a dipeptidyl peptidase-4 inhibitor, decreases systolic blood pressure in Japanese hypertensive patients with type 2 diabetes. Tohoku J Exp Med 223(2):133–135PubMedCrossRef

68.

Yu M, Moreno C, Hoagland KM et al (2003) Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats. J Hypertens 21(6):1125–1135PubMedCrossRef

69.

Yamamoto H, Lee CE, Marcus JN et al (2002) Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest 110(1):43–52PubMed

70.

Barragan JM, Eng J, Rodriguez R, Blazquez E (1999) Neural contribution to the effect of glucagon-like peptide-1-(7-36) amide on arterial blood pressure in rats. Am J Physiol 277(5 Pt 1):E784–E791PubMed

71.

Bojanowska E, Stempniak B (2000) Effects of centrally or systemically injected glucagon-like peptide-1 (7–36) amide on release of neurohypophysial hormones and blood pressure in the rat. Regul Pept 91(1–3):75–81

72.

Goto H, Nomiyama T, Mita T et al (2011) Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces intimal thickening after vascular injury. Biochem Biophys Res Commun 405(1):79–84PubMedCrossRef

73.

Arakawa M, Mita T, Azuma K et al (2010) Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes 59(4):1030–1037PubMedCrossRef

74.

Marx N, Burgmaier M, Heinz P et al (2010) Glucagon-like peptide-1(1–37) inhibits chemokine-induced migration of human CD4-positive lymphocytes. Cell Mol Life Sci 67(20):3549–3555PubMedCrossRef

75.

Ishibashi Y, Nishino Y, Matsui T et al (2011) Glucagon-like peptide-1 suppresses advanced glycation end product-induced monocyte chemoattractant protein-1 expression in mesangial cells by reducing advanced glycation end product receptor level. Metabolism 60(9):1271–1277PubMedCrossRef

76.

Liu H, Hu Y, Simpson RW, Dear AE (2008) Glucagon-like peptide-1 attenuates tumour necrosis factor-alpha-mediated induction of plasminogen [corrected] activator inhibitor-1 expression. J Endocrinol 196(1):57–65PubMedCrossRef

77.

Liu H, Dear AE, Knudsen LB, Simpson RW (2009) A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules. J Endocrinol 201(1):59–66PubMedCrossRef

78.

Hattori Y, Jojima T, Tomizawa A et al (2010) A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells. Diabetologia 53(10):2256–2263PubMedCrossRef

79.

Ku HC, Chen WP, Su MJ (2010) GLP-1 signaling preserves cardiac function in endotoxemic Fischer 344 and DPP4-deficient rats. Naunyn Schmiedebergs Arch Pharmacol 382(5–6):463–474

80.

Oeseburg H, de Boer RA, Buikema H et al (2010) Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A. Arterioscler Thromb Vasc Biol 30(7):1407–1414PubMedCrossRef

81.

Matsui T, Nishino Y, Takeuchi M, Yamagishi S (2011) Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product-receptor axis. Pharmacol Res 63(5):383–388PubMedCrossRef

82.

Zinman B, Gerich J, Buse JB et al (2009) Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 32(7):1224–1230PubMedCrossRef

83.

Buse JB, Rosenstock J, Sesti G et al (2009) Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 374(9683):39–47PubMedCrossRef

84.

Meier JJ, Gethmann A, Götze O et al (2006) Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans. Diabetologia 49(3):452–458PubMedCrossRef

85.

Best JH, Hoogwerf BJ, Herman WH et al (2011) Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database. Diabetes Care 34(1):90–95PubMedCrossRef

Titel: Kardiovaskuläre Effekte inkretinbasierter Therapien
verfasst von: Dr. M. Lehrke
N. Marx
Publikationsdatum: 01.05.2012
Verlag: Urban and Vogel
Erschienen in: Herz / Ausgabe 3/2012
Print ISSN: 0340-9937
Elektronische ISSN: 1615-6692
DOI: https://doi.org/10.1007/s00059-012-3599-8

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Kardiovaskuläre Effekte inkretinbasierter Therapien

Zusammenfassung

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

Update Kardiologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2012

Atrial fibrillation and diabetes mellitus

SREBP-1 und Fettleber

Acute stent thrombosis during percutaneous coronary intervention

Aneurysmatic disease in patients with Takayasu disease: a case review

Kardiale Bildgebung beim (asymptomatischen) Diabetiker

Witnessed pulmonary vein arrest—endoscopically observed conversion of atrial fibrillation into sinus rhythm by laser balloon ablation

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

Update Kardiologie